Drug
Srf617
Srf617: highest development phase Phase 2, developed by Coherus BioSciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Coherus BioSciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRF617 NCT05177770 | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
Latest
No recent events.
Follow Srf617 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.